<DOC>
	<DOCNO>NCT00139932</DOCNO>
	<brief_summary>This study conduct determine co-administration formoterol fumarate tiotropium bromide effective use tiotropium bromide alone patient COPD .</brief_summary>
	<brief_title>Tiotropium Bromide Alone v Tiotropium Bromide Formoterol Fumarate Subjects With COPD ( Study P04272 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Subjects must clinical history COPD . Subjects must current cigarette smoker exsmokers stop smoke least 3 month prior screen visit ( V1 ) . Subjects must smoke history least 10 packyears ( 20 cigarette per pack ) . Packyears calculate multiplying average pack cigarettes smoked per day time number year . Subjects stable inhaled corticosteroid allow enrolled remain treatment throughout study . Subjects must willing give write informed consent able adhere dose visit schedule . Subjects must agree inform usual treat physician participation study . Female subject childbearing potential must negative urine pregnancy test prior randomization study Nonpregnant woman childbearing potential must use medically acceptable , adequate form birth control . Subjects current past history clinically relevant asthma . Subjects quit smoking le 3 month prior Screening visit ( V1 ) . Subjects require ventilator support respiratory failure within last year . Subjects clinically significant lung disease COPD , e.g. , bronchiectasis , sarcoidosis , pulmonary fibrosis , tuberculosis , etc . Subjects undergone lobectomy , pneumonectomy lung volume reduction surgery . Subjects lung cancer diagnose treat within last five year . Subjects require nasal continuous positive airway pressure ( CPAP ) bilevel positive airway pressure ( BiPAP ) . Subjects initiate pulmonary rehabilitation within past 3 month . Subjects use oxygen &gt; = 2 liter per minute &gt; 2 hour per day . Subjects require chronic prophylactic treatment antibiotic . Subjects significant renal , hepatic , cardiovascular ( include cor pulmonale ) , metabolic , neurologic , hematologic , gastrointestinal , cerebrovascular significant medical illness disorder , judgment Investigator , may interfere study require treatment may affect evaluation efficacy safety study drug . Subjects clinically significant abnormality chest xray ( evidence COPD ) Screening visit within previous year . Women pregnant breastfeeding . Subjects adhere concomitant medication restriction prohibition . Subjects use investigational product within 30 day , 3 month biologic unknown halflife , prior Baseline Visit ( V3 ) . Subjects part staff family member staff personnel directly involve study . Subjects chronic narrowangle glaucoma . Subjects symptomatic prostatic hyperplasia bladderneck obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>